Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

Vivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company’s formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc.
MassDevice

Orchestra BioMed to pick up $21M through Haemonetics’ acquisition of Vivasure

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

The Company's common shares are expected to begin trading on a post-consolidated basis at the opening of the market on January 20, 2026. Following the consolidation, the Company's common shares will ...

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

The Board’s decision followed a thorough and strategic review of the Company’s financial position, capital structure, prevailing market conditions, and Nasdaq listing considerations. The Strategy is ...

Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
The Manila Times

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...

BioMed Realty and TransMedics Announce 498,000-Square-Foot Lease at Assembly Innovation Park

Situated in Somerville's mixed-use urban development area known as Assembly Square, and with its close proximity to Interstate 93 and the MBTA Orange Line, Assembly Innovation Park offers exceptional ...